107 related articles for article (PubMed ID: 1908753)
1. The relation between pharmacokinetics and endocrine effects of buserelin implants in patients with mastalgia.
Klijn JG; van Geel B; de Jong FH; Sandow J; Krauss B
Clin Endocrinol (Oxf); 1991 Apr; 34(4):253-8. PubMed ID: 1908753
[TBL] [Abstract][Full Text] [Related]
2. Long-acting gonadotrophin releasing hormone agonist implant causes variable duration of suppression of ovarian steroid and inhibin secretion.
Fraser HM; Haining R; Cowen GM; Sandow J; Smith KB; Smith SK
Clin Endocrinol (Oxf); 1992 Jan; 36(1):97-104. PubMed ID: 1559303
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and endocrine effects of slow release formulations of LHRH analogues.
Sandow J; Stoeckemann K; Jerabek-Sandow G
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):925-31. PubMed ID: 2126737
[TBL] [Abstract][Full Text] [Related]
4. An implant of a gonadotropin releasing hormone agonist (buserelin) which suppresses ovarian function in the macaque for 3-5 months.
Fraser HM; Sandow J; Seidel H; von Rechenberg W
Acta Endocrinol (Copenh); 1987 Aug; 115(4):521-7. PubMed ID: 3115020
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and endocrine effects of the LHR analogue buserelin after subcutaneous implantation of a slow release preparation in prostatic cancer patients.
Blom JH; Hirdes WH; Schröder FH; de Jong FH; Kwekkeboom DJ; van't Veen AJ; Sandow J; Krauss B
Urol Res; 1989; 17(1):43-6. PubMed ID: 2493705
[TBL] [Abstract][Full Text] [Related]
6. Effects of the luteinizing-hormone-releasing hormone (LHRH) antagonist ramorelix (hoe013) and the LHRH agonist buserelin on dimethylbenz[]anthracene-induced mammary carcinoma: studies with slow-release formulations.
Stoeckemann K; Sandow J
J Cancer Res Clin Oncol; 1993; 119(8):457-62. PubMed ID: 8509436
[TBL] [Abstract][Full Text] [Related]
7. Serum concentration and urinary excretion of the luteinizing hormone-releasing hormone agonist buserelin in patients with endometriosis.
Kiesel L; Sandow J; Bertges K; Jerabek-Sandow G; Trabant H; Runnebaum B
J Clin Endocrinol Metab; 1989 Jun; 68(6):1167-73. PubMed ID: 2498387
[TBL] [Abstract][Full Text] [Related]
8. Controlled release of a GnRH agonist from a polyhydroxybutyric acid implant: reversible suppression of the menstrual cycle in the macaque.
Fraser HM; Sandow J; Seidel HR; Lunn SF
Acta Endocrinol (Copenh); 1989 Dec; 121(6):841-8. PubMed ID: 2514544
[TBL] [Abstract][Full Text] [Related]
9. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates.
Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
Fertil Steril; 1998 Dec; 70(6):1063-9. PubMed ID: 9848296
[TBL] [Abstract][Full Text] [Related]
10. The effects of buserelin microparticles on ovarian function in healthy women.
Meyer BH; Muller FO; de la Rey N; Luus HG; Rosenkranz B
S Afr Med J; 1995 Aug; 85(8):766-7. PubMed ID: 8553146
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of the gonadotropin-releasing hormone agonist buserelin after injection of a slow-release preparation in normal men.
Behre HM; Sandow J; Nieschlag E
Arzneimittelforschung; 1992 Jan; 42(1):80-4. PubMed ID: 1586387
[TBL] [Abstract][Full Text] [Related]
12. Ovarian sonographic findings during intermittent intranasal luteinizing hormone-releasing hormone agonist sequentially combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N; Bastide A
Fertil Steril; 1987 Jan; 47(1):60-6. PubMed ID: 2947818
[TBL] [Abstract][Full Text] [Related]
13. Use of buserelin in an IVF programme for pituitary-ovarian suppression prior to ovarian stimulation with exogenous gonadotrophins.
Ibrahim ZH; Matson PL; Buck P; Critchlow JD; Newman MC; Horne G; Hughes S; Lieberman BA
Hum Reprod; 1990 Apr; 5(3):258-62. PubMed ID: 2112554
[TBL] [Abstract][Full Text] [Related]
14. Pituitary and ovarian suppression rate after high dosage of gonadotropin-releasing hormone agonist.
Bider D; Ben-Rafael Z; Shalev J; Goldenberg M; Mashiach S; Blankstein J
Fertil Steril; 1989 Apr; 51(4):578-81. PubMed ID: 2494078
[TBL] [Abstract][Full Text] [Related]
15. Pituitary-testicular function is suppressed by an LHRH antagonist but not by an LHRH agonist in the marmoset monkey.
Lunn SF; Dixson AF; Sandow J; Fraser HM
J Endocrinol; 1990 May; 125(2):233-9. PubMed ID: 2165119
[TBL] [Abstract][Full Text] [Related]
16. Acute pituitary-ovarian response during chronic luteinizing hormone-releasing hormone agonist administration in polycystic ovarian syndrome.
Faure N; Lemay A
Clin Endocrinol (Oxf); 1988 Oct; 29(4):403-10. PubMed ID: 3150825
[TBL] [Abstract][Full Text] [Related]
17. Cyclical breast pain and swelling in relation to differing patterns of suppression of ovarian activity with the luteinizing hormone-releasing hormone analogue buserelin acetate: case report.
Magill P; Barlow D
Fertil Steril; 1995 Jan; 63(1):193-5. PubMed ID: 7805912
[TBL] [Abstract][Full Text] [Related]
18. [Successful treatment of endometriosis in women with continuous subcutaneous infusion of gonadotropin-releasing hormone agonist (GnRH-A)].
Masaoka K; Kitazawa M; Kumasaka T
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Apr; 41(4):405-11. PubMed ID: 2501437
[TBL] [Abstract][Full Text] [Related]
19. Escape from the down-regulation of the pituitary-ovarian axis following decreased infusion of luteinizing hormone-releasing hormone agonist.
Lemay A; Sandow J; Quesnel G; Bergeron J; Mérat P
Fertil Steril; 1988 May; 49(5):802-8. PubMed ID: 3129314
[TBL] [Abstract][Full Text] [Related]
20. Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase.
Healy DL; Lawson SR; Abbott M; Baird DT; Fraser HM
J Clin Endocrinol Metab; 1986 Sep; 63(3):619-25. PubMed ID: 3090092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
